Mary E Strek

List of Publications by Year
in descending order

65 papers	5,005 citations	147566 31 h-index	118652 62 g-index
68 all docs	68 docs citations	68 times ranked	4122 citing authors

#	Article	IF	Citations
1	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
2	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
3	Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Chest, 2013, 143, 814-824.	0.4	257
4	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1475-1482.	2.5	257
5	Autoimmune-Featured Interstitial Lung Disease. Chest, 2011, 140, 1292-1299.	0.4	236
6	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	3.1	219
7	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
8	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research, 2019, 20, 205.	1.4	166
9	The Diagnosis and Treatment of Antisynthetase Syndrome. Clinical Pulmonary Medicine, 2016, 23, 218-226.	0.3	151
10	Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respiratory Medicine, 2017, 123, 56-62.	1.3	119
11	Telomere length and genetic variant associations with interstitial lung disease progression and survival. European Respiratory Journal, 2019, 53, 1801641.	3.1	119
12	Recent Advances in Severe Asthma. Chest, 2020, 157, 516-528.	0.4	96
13	Asthma Outcomes and Management DuringÂPregnancy. Chest, 2018, 153, 515-527.	0.4	91
14	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
15	Bronchiectasis in a Diverse US Population. Chest, 2012, 142, 159-167.	0.4	88
16	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 117-122.	1.3	85
17	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research, 2017, 3, 00016-2017.	1.1	84
18	Comprehensive Care of the Lung Transplant Patient. Chest, 2017, 152, 150-164.	0.4	74

#	Article	IF	Citations
19	Barriers to Optimal Palliative Care of Lung Transplant Candidates. Chest, 2013, 143, 736-743.	0.4	60
20	Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 692-700.	0.4	50
21	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. American Journal of Roentgenology, 2017, 208, 1229-1236.	1.0	47
22	Prevalence and Clinical Significance ofÂAntineutrophil Cytoplasmic Antibodies inÂNorth American Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 715-723.	0.4	45
23	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 147.	0.8	42
24	Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory Medicine, 2016, 114, 53-60.	1.3	42
25	COVIDOSE: A Phase II Clinical Trial of Lowâ€Dose Tocilizumab in the Treatment of Noncritical COVIDâ€19 Pneumonia. Clinical Pharmacology and Therapeutics, 2021, 109, 688-696.	2.3	42
26	Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. Journal of Rheumatology, 2017, 44, 1612-1618.	1.0	40
27	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest, 2018, 153, 349-360.	0.4	40
28	Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest, 2020, 158, 252-263.	0.4	40
29	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
30	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39
31	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. European Respiratory Journal, 2018, 51, 1800255.	3.1	37
32	Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respiratory Research, 2019, 20, 253.	1.4	35
33	Allergic and Noninvasive Infectious Pulmonary Aspergillosis Syndromes. Clinics in Chest Medicine, 2017, 38, 521-534.	0.8	33
34	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
35	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
36	Difficult Asthma. Proceedings of the American Thoracic Society, 2006, 3, 116-123.	3.5	30

#	Article	IF	Citations
37	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
38	Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 442-453.	2.7	28
39	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. American Journal of Roentgenology, 2018, 210, 1034-1041.	1.0	26
40	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
41	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. European Respiratory Journal, 2020, 56, 2001205.	3.1	24
42	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	2.5	23
43	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19
44	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
45	Consensus guidelines for asthma therapy. Annals of Allergy, Asthma and Immunology, 2001, 86, 40-44.	0.5	18
46	Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest, 2021, 160, 209-218.	0.4	18
47	Automated CT Analysis of Major Forms of Interstitial Lung Disease. Journal of Clinical Medicine, 2020, 9, 3776.	1.0	14
48	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest, 2017, 152, 683-685.	0.4	12
49	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12
50	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
51	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. Frontiers in Medicine, 2017, 4, 170.	1.2	10
52	A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria. European Respiratory Journal, 2016, 48, 1813-1814.	3.1	8
53	Hospitalizations in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 257.	1.4	8
54	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. Respiratory Medicine: X, 2019, 1, 100002.	1.4	7

#	Article	IF	Citations
55	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatology Advances in Practice, 2021, 5, ii1-ii9.	0.3	7
56	Gender equity in interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 842-843.	5.2	6
57	Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard. Frontiers in Medicine, 2022, 9, 864658.	1.2	6
58	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5
59	Gender in idiopathic pulmonary fibrosis diagnosis: time to address unconscious bias. Thorax, 2020, 75, 365-366.	2.7	4
60	Improving Asthma Management. Chest, 2012, 142, 1085-1087.	0.4	3
61	Systemic sclerosisâ€associated interstitial lung disease: Role of the oesophagus in outcomes. Respirology, 2018, 23, 885-886.	1.3	3
62	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
63	Response. Chest, 2016, 149, 600-601.	0.4	0
64	Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease. ERJ Open Research, 2021, 7, 00254-2021.	1.1	0
65	Occupational Exposures in Rheumatoid Arthritis-Related Airway Disease: A Missing Link?. Annals of the American Thoracic Society, 2022, , .	1.5	0